US2020009158A1PendingUtilityA1
Sulfated-Oxysterol and Oxysterol Sulfation by Hydroxysterol Sulfotransferase Promote Lipid Homeostasis and Liver Tissue Regeneration
Est. expiryApr 6, 2031(~4.7 yrs left)· nominal 20-yr term from priority
Inventors:Shunlin Ren
A61P 9/10A61P 9/00A61P 3/10A61P 3/06A61P 29/00A61P 1/16A61P 1/00A61K 48/005C12N 9/13C12N 2799/022A01K 67/027A01K 2227/105A01K 2267/0362A01K 2207/25A61K 31/575
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods and compositions for the prevention and treatment of liver damage or disease in a subject in need thereof are provided. The methods involve providing the sulfated oxysterol 25-hydroxycholesterol-3-sulfate (25HC3S) to the subject e.g. by 1) administering 25HC3S to the subject; or 2) overexpressing, in the subject, the hydroxysterol sulfotransferase enzyme SULT2B1b, which catalyzes the sulfation of 25-hydroxycholesterol (25HC) to form 25HC3S.
Claims
exact text as granted — not AI-modified1 - 25 . (canceled)
26 . A method of treating a subject with hepatitis caused by consumption of alcohol comprising administering to the subject a composition comprising a therapeutically effective amount of 25-hydroxycholesterol-3-sulfate (25HC3S) and a pharmaceutically acceptable excipient.
27 . The method of claim 26 , wherein the 25HC3S comprises a sodium salt thereof.
28 . The method of claim 26 , wherein the pharmaceutically acceptable excipient comprises water.
29 . The method of claim 26 , wherein the composition further comprises a pH buffering agent.
30 . The method of claim 26 , wherein the administration comprises at least one of oral administration, enteric administration, sublingual administration, transdermal administration, intravenous administration, peritoneal administration, parenteral administration, administration by injection, subcutaneous injection, and intramuscular injection.
31 . The method of claim 26 , wherein the administration comprises at least one of oral administration and intravenous administration.
32 . The method of claim 26 , wherein the 25HC3S is administered in an amount ranging from 0.1 mg/kg to 100 mg/kg, based on body mass of the subject.
33 . The method of claim 26 , wherein the 25HC3S is administered in an amount ranging from 1 mg/kg to 10 mg/kg, based on body mass of the subject.
34 . The method of claim 28 , wherein the 25HC3S comprises a sodium salt thereof.
35 . The method of claim 29 , wherein the 25HC3S comprises a sodium salt thereof.
36 . The method of claim 30 , wherein the 25HC3S comprises a sodium salt thereof.
37 . The method of claim 31 , wherein the 25HC3S comprises a sodium salt thereof.
38 . The method of claim 32 , wherein the 25HC3S comprises a sodium salt thereof.
39 . The method of claim 33 , wherein the 25HC3S comprises a sodium salt thereof.
40 . The method of claim 28 , wherein the administration comprises at least one of oral administration and intravenous administration.
41 . The method of claim 29 , wherein the administration comprises at least one of oral administration and intravenous administration.
42 . The method of claim 32 , wherein the administration comprises at least one of oral administration and intravenous administration.
43 . The method of claim 33 , wherein the administration comprises at least one of oral administration and intravenous administration.Join the waitlist — get patent alerts
Track US2020009158A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.